换组蛋白质疗法

融合蛋白质及其他的疗法

1月9日～10日

藉由组合创意和生物学产生之换组蛋白质疗法，是与迄今可提高生物学疗法的安全性和效果不同的新「设计」。此部会针对抗体以外生物医药品应留意的世界，介绍已获得认可的产品和现在属于临床开发阶段的产品等各种治疗用融合蛋白质。此外，亦预定举行由业界的意见领袖介绍特异性构造体和免疫原性未解决课题中已达成的重要进步之研习会。

实现融合蛋白疗法的可能性

OPENING KEYNOTE PRESENTATION:

George Yancopoulos, Executive Vice President, CSO & President, Regeneron Pharmaceuticals, Inc.

FEATURED PRESENTATION:
Therapeutic Fusion Proteins and Their Modular Components: From Albumin to XL-Protein

Stefan Schmidt, Ph.D., M.B.A., CSO, ERBiotech

蛋白质间相互作用的标的化

Targeting Protein-Protein Interactions with Engineered Cyclotides

Julio Camarero, Ph.D., Associate Professor, Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles

Protein-Fragment Complementation and Semi-Rational Design: Engineering Specific Antagonists of Protein-Protein Interactions

Jody M. Mason, Ph.D., Senior Lecturer, Biochemistry, University of Essex

克服各种课题之治疗法设计的革新

XTENylation Enables Monthly Dosing of Biopharmaceuticals

Volker Schellenberger, Ph.D., Vice President, Drug Discovery, Amunix

From Clinical Imaging to Serum Half-Life Extension of Affibody Molecules & Biopharmaceuticals

Joachim Feldwisch, Ph.D., Director, Preclinical Development, Affibody AB

多功能性的开发

Multifunctional Fusion Proteins Based on Engineered Antibody Domains

Dimiter Dimitrov, Ph.D., Head, Protein Interaction Group; Senior Investigator, Center for Cancer Research, NCI-Frederick, NIH

Multifunctional Nanolipoprotein Particles using Telodendrimer Chemistry for Immunomodulation

Matthew Coleman, Ph.D., Associate Adjunct Professor, Radiation Oncology, University of California, Davis; Senior Scientist, Biology and Biotechnology, Lawrence Livermore National Laboratory

Trivalent Atrimers Therapeutics: A New Grasp on Receptors for Potent Protein Therapeutics

Anke Kretz-Rommel, Ph.D., Vice President, Research & Development, Anaphore, Inc.

开发与疾病作战的技术

Engineered Receptor Tyrosine Kinase Domains for Treatment of Metastatic Cancers

Jennifer Cochran, Ph.D., Assistant Professor, Bioengineering, Stanford University

融合蛋白质技术

Kunitz Domain Fusion Proteins for in vitro Screening and in vivo Analysis

Andrew Nixon, Ph.D., Vice President, Lead Discovery & Biochemistry, Discovery Research, Dyax Corp.